Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing On The Nasdaq Stock Market Subject To Conditions
Portfolio Pulse from Benzinga Newsdesk
TransCode Therapeutics has been granted an extension for continued listing on the Nasdaq Stock Market, subject to certain conditions. The extension was granted by a Nasdaq Panel.
October 27, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
TransCode Therapeutics' continued listing on the Nasdaq is subject to certain conditions. This could potentially impact the company's stock price.
The news of the extension for continued listing on the Nasdaq could potentially impact the stock price of TransCode Therapeutics. However, the impact will depend on whether the company meets the conditions set by the Nasdaq Panel.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100